ABSTRACT
OBJECTIVES: The aim of our work was to assess the role of tau protein, beta amyloid and cystatin C in diagnosis of Alzheimer dementia (AD) and other neurodegenerative diseases (NDs). METHODS: The levels of tau protein, beta amyloid and cystatin C were assessed in a set of 79 patients with ND (38 men and 41 women; aged 22-90 years; mean, 61.6 +/- 15.6 years) and in a control group of 79 subjects with a healthy central nervous system (38 men and 41 women; aged 20-91 years; mean, 61.5 +/- 15.1 years). RESULTS: When compared with the subjects in the control group, a statistically significant decrease in tau protein levels was found in patients with ND, an increase in tau protein levels in patients with AD and an increase in cystatin C cerebrospinal fluid/serum index in the ND + AD group. DISCUSSION: Our work only confirmed the previously reported results in part. Although tau protein seems to be a quite reliable marker of AD, the role of beta amyloid in AD diagnosis remains at the least questionable. In the case of cystatin C, our results would seem to confirm the views of certain authors that cystatin C will probably not become a new 'revolutionary' marker contributing to differential diagnostics.
Subject(s)
Alzheimer Disease/diagnosis , Amyloid beta-Peptides , Cystatin C , tau Proteins , Adult , Aged , Aged, 80 and over , Aging/cerebrospinal fluid , Alzheimer Disease/cerebrospinal fluid , Amyloid beta-Peptides/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Cystatin C/cerebrospinal fluid , Diagnosis, Differential , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Reference Values , Statistics, Nonparametric , tau Proteins/cerebrospinal fluidABSTRACT
To assess the role of tau protein, beta-amyloid(1-42) and cystatin C in the diagnostics of Alzheimer dementia (AD) and other neurodegenerative diseases (ND) by comparing to the control groups (CG). The levels of tau protein, beta-amyloid(1-42) and cystatin C were assessed in the set of 69 patients (AD + ND, 33 males, 36 females, aged 22-90, mean 60.5 + 16.1 years), and in a control group of 69 subjects without the affection of the central nervous system (CGAD + CGND, 33 males, 36 females, aged 20-91, mean 60.5 + 16.0 years). Statistically significant increased tau protein levels (P = 0.0001) and index tau/beta-amyloid(1-42) levels (P = 0.0002) were shown in the group of AD patients, compared to the group of ND patients. One-way ANOVA analysis with Bonferonni post hoc test did not show any significant differences of the cystatin C values between any of the compared groups. ROC analysis showed at least one tie between the positive actual state group (AD) and the negative actual state group (ND) by CSF cystatin C and at least one tie between the positive actual state group and the negative actual state group by CSF tau protein. Our study confirmed previously reported results only in part. While tau protein seems to be quite a reliable marker of AD, the role of beta-amyloid(1-42) and cystatin C in AD diagnosis remains at least questionable.
Subject(s)
Alzheimer Disease/diagnosis , Amyloid beta-Peptides/cerebrospinal fluid , Cystatin C/cerebrospinal fluid , Peptide Fragments/cerebrospinal fluid , tau Proteins/cerebrospinal fluid , Adult , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/analysis , Biomarkers/analysis , Biomarkers/cerebrospinal fluid , Cystatin C/analysis , Female , Humans , Male , Middle Aged , Nerve Degeneration/cerebrospinal fluid , Nerve Degeneration/diagnosis , Nerve Degeneration/physiopathology , Peptide Fragments/analysis , Predictive Value of Tests , Up-Regulation/physiology , Young Adult , tau Proteins/analysisABSTRACT
OBJECTIVE: Evaluation of selected scales of the Minnesota Multiphasis Personality Inventory-2 (MMPI-2) within the frame of psychosomatic aspects of gynecological oncology. DESIGN: Assessment of actual emotional state and its comparison with the general personality traits of patients before a surgery for gynecologic malignancy. SETTING: Department of Obstetrics and Gynecology, University Hospital Medical Faculty PU, Olomouc. METHODS: The study group included 40 patients before the operation and histological confirmation of the diagnosis of oncological disease in whom the indicators of emotional status and personality structure was assessed. The standardized MMPI-2 was used for differenciation of clinical depression, anxiety and psychastenic traits. The ability of patients to participate in the study and adequately express themselves about their emotional status was examined to estimate the validity of administered data. RESULTS: Significantly higher scores in the selected scales of the standardized MMMPI-2 were found in our study group compared to general population. The most marked differences were observed in anxiety and clinical manifestation of depresive symptoms. CONCLUSION: Based on the configuration of the personality scales it is therefore possible to accept the research hypothesis that patients in this group are predisponised to anxiousness as a personality trait even before the final confirmation of their suspected oncological diagnosis.
